For a world paralyzed by coronavirus, salvation requires a vaccine.
But in the United States, where at least 4.6 million more people have become inflamed and nearly 155,000 have died, the promise of this vaccine is hampered by an annoying epidemic that preceded COVID-19: obesity.
Scientists know that vaccines designed for the public against influenza, hepatitis B, tetanus and rabies would likely be less effective in obese adults than in the general population, making them more vulnerable to infections and disease. There is little explanation why, according to obesity researchers, that COVID-19 vaccines will be different.
“Will we have a COVID vaccine next year for the obese? No way,” said Raz Shaikh, an associate professor of nutrition at the University of North Carolina-Chapel Hill.
“Do you paint on the obese? Our prediction is no.”
Subscribe to the khN weekly weekly newsletter.
More than 107 million American adults are obese and their ability to safely repaint, care for their families and return to life may be reduced if the coronavirus vaccine provides them with low immunity.
In March, even at the beginning of the global pandemic, an unnoticed examination of China found that chinese patients heavier with COVID-19 were more likely to die than the thintest, suggesting a long-term long-term expected dangerous in the United States, whose population is among the heaviest. around the world.
And then came that long term.
While extensive care centers in New York, New Jersey and patient-filled, the Federal Centers for Disease Control and Prevention warned that obese Americans with a frame mass index of 40 or more, known as morbid obesity or approximately one hundred pounds of obesity, were among the teams at risk of seriously falling ill with COVID-19. Approximately 9% of U.S. adults fall into this category.
As the weeks passed and a clearer picture of hospitalized patients emerged, federal fitness officials expanded their warnings to include others with a body mass index of 30 or more. This has particularly expanded the ranks of those vulnerable to the most severe cases of infection, to 42.4% of American adults.
Obesity has long been known as one of the main death threats from cardiovascular disease and cancer. But scientists in the emerging immunometabolism chart find that obesity also interferes with the body’s immune response, exposing other obese people to a greater threat of infection with pathogens such as influenza and the new coronavirus. In the case of the flu, obesity has something that makes it harder for adults to breasts rather than infection. The query is whether this will be true for COVID-19.
A healthy immune formula activates and disables inflammation as needed, white blood cells and the delivery of proteins to fight infections. Vaccines exploit this inflammatory response. But blood tests show that other obese people and others with metabolic threat points such as upper blood pressure and upper blood sugar delight in a state of mild chronic inflammation; inflammation turns on and stays on.
Fatty tissue in the stomach, liver and other organs is not inert; specialized cells that send molecules, such as the hormone leptin, that scientists suspect induce this state of chronic inflammation. While precise biological mechanisms are still being studied, chronic inflammation appears to interfere with the immune reaction to vaccines, which in all likelihood subjects other obese people to preventable diseases even after vaccination.
An effective vaccine feeds a controlled burning inside the body, burning in cellular reminiscences a simulated invasion that never occurred.
Evidence that obese Americans have a strong reaction to non-unusual vaccines was first observed in 1985 when obese hospital workers who won the hepatitis B vaccine showed a significant minimum in coverage 11 months later that it was not observed in non-obese workers. This discovery was replicated in a follow-up study that used longer needles to ensure that the vaccine was injected into the muscle and not fat.
Researchers have discovered similar disorders with the hepatitis A vaccine, and other studies have shown a significant decrease in antibody coverage induced by tetanus and rabies vaccines in obese people.
“Obesity is a serious global problem, and the suboptimal immune responses induced by the vaccine seen in the obese population should be ignored,” researchers from the Mayo Clinic Vaccine Research Group argued in a 2015 study published in the journal Vaccine.
Vaccines are also known to be less effective in the elderly, which is why other people over the age of 65 get a supercharged flu vaccine each year that includes many more influenza virus antigens to help their immune response.
On the other hand, reduced coverage of the obese population (adults and young people) has been largely ignored.
“I’m not sure why the effectiveness of vaccines in this population has not been better reported,” said Catherine Andersen, assistant professor of biology at Fairfield University, who studies obesity and metabolic diseases. “This is a missed opportunity for further public intervention on fitness.”
In 2017, UNC-Chapel Hill scientists provided a key clue to the limitations of the flu vaccine. In a paper published in the International Journal of Obesity, they showed for the first time that vaccinated obese adults were twice as likely as healthy-weight adults to expand influenza or a flu-like disease.
Surprisingly, they found that obese adults produced a point of antibodies opposed to the flu vaccine, and still responded badly.
“That was the mystery,” said Chad Petit, an influenza virologist at the University of Alabama.
One hypothesis, Petit said, is that obesity can cause metabolic deregulation of T cells, the white blood cells of the immune response. “It’s not second to none,” said Petit, who researches COVID-19 in obese patients. “We can design better vaccines that can succeed over this gap.”
Historically, other people with a higher BMI have occasionally been excluded from drug trials because they suffer from chronic diseases that can mask the results. Ongoing clinical trials to verify the protection and efficacy of a coronavirus vaccine do not come to the exclusion of BMI and will come with obese individuals, said Dr. Larry Corey of the Fred Hutchinson Cancer Research Center, which oversees Phase 3 trials sponsored by the National Institutes of Health.
Although trial coordinators do not do so in particular about obesity as a prospective complication, Corey said, the participants’ BMI will be documented and the effects assessed.
Dr. Timothy Garvey, endocrinologist and director of diabetes studies at the University of Alabama, was one of those who noted that, despite persistent questions, it is safer for obese people to get lost.
“The flu vaccine still works in obese patients, but not so well,” Garvey said. “We need them to be drained.”
Share this story:
For a world paralyzed by coronavirus, salvation requires a vaccine.
But in the United States, where at least 4.6 million more people have become inflamed and nearly 155,000 have died, the promise of this vaccine is hampered by an annoying epidemic that preceded COVID-19: obesity.
Scientists know that vaccines designed for the public against influenza, hepatitis B, tetanus and rabies would likely be less effective in obese adults than in the general population, making them more vulnerable to infections and disease. There is little explanation why, according to obesity researchers, that COVID-19 vaccines will be different.
“Will we have a COVID vaccine next year for the obese? No way,” said Raz Shaikh, an associate professor of nutrition at the University of North Carolina-Chapel Hill.
“Do you paint on the obese? Our prediction is no.”
For a world paralyzed by coronavirus, salvation requires a vaccine.
But in the United States, where at least 4.6 million people have become inflamed and have only died of about 155,000, the promise of this vaccine is hampered by an irritating epidemic that preceded COVID-19: obesity.
Scientists know that vaccines designed for the public against influenza, hepatitis B, tetanus and rabies would likely be less effective in obese adults than in the general population, making them more vulnerable to infections and disease. There is little explanation for why, researchers say in obesity, that COVID-19 vaccines will be different.
“Will we have a COVID vaccine next year for the obese? No way,” said Raz Shaikh, an associate professor of nutrition at the University of North Carolina-Chapel Hill.
“Do you paint on the obese? Our prediction is no.”
More than 107 million American adults are obese and their ability to safely repaint, care for their families and return to life may be reduced if the coronavirus vaccine provides them with low immunity.
In March, even at the beginning of the global pandemic, an unnoticed examination of China found that Chinese patients heavier with COVID-19 were more likely to die than the thintest, suggesting a long-term expected dangerous term in the United States, whose population is among the heaviest. around the world.
And then came that long term.
While extensive care centers in New York, New Jersey and patient-filled, the Federal Centers for Disease Control and Prevention warned that obese Americans with a frame mass index of 40 or more, known as morbid obesity or about one hundred pounds of obesity, were among the maximum at risk of being seriously ill with COVID-19 approximately 9% of U.S. adults fall into this category.
As the weeks passed and a clearer picture of hospitalized patients emerged, federal fitness officials expanded their warnings to include others with a body mass index of 30 or more. This has particularly expanded the ranks of people vulnerable to the most severe cases of infection to 42.4% of American adults.
Obesity has long been known to be a major threat to death from cardiovascular disease and cancer. But scientists in the emerging immunometabolism chart find that obesity also interferes with the body’s immune response, exposing other obese people to a greater threat of infection with pathogens such as influenza and the new coronavirus. In the case of influenza, obesity has emerged as a difficult thing for adults to vaccinate against infection. The question is whether this will be true for COVID-19.
A healthy immune formula activates and disables inflammation as needed, white blood cells and the delivery of proteins to fight infections. Vaccines exploit this inflammatory response. But blood tests show that other obese people and others with metabolic threat points, such as high blood pressure and higher blood sugar level, delight in a state of mild chronic inflammation; inflammation turns on and stays on.
Fatty tissue in the stomach, liver and other organs is not inert; specialized cells that send molecules, such as the hormone leptin, that scientists suspect induce this state of chronic inflammation. While precise biological mechanisms are still under study, chronic inflammation appears to interfere with the immune reaction to vaccines, and is likely to subject other obese people to preventable diseases even after vaccination.
An effective vaccine feeds a controlled burning inside the body, burning in cellular reminiscences a simulated invasion that never occurred.
Evidence that obese Americans have a strong reaction to non-unusual vaccines was first observed in 1985 when obese hospital workers who won the hepatitis B vaccine showed a significant reduction in coverage 11 months later that was not observed in non-obese workers. This discovery was replicated in a follow-up study that used longer needles to ensure that the vaccine was injected into the muscle and not fat.
Researchers have discovered similar disorders with the hepatitis A vaccine, and other studies have shown a significant decrease in antibody coverage induced by tetanus and rabies vaccines in obese people.
“Obesity is a serious global problem, and the suboptimal immune responses induced by the vaccine seen in the obese population should be ignored,” researchers from the Mayo Clinic Vaccine Research Group argued in a 2015 study published in the journal Vaccine.
Vaccines are also known to be less effective in the elderly, which is why other people age 65 and older get a supercharged flu vaccine each year that contains many more influenza virus antigens to help their immune response.
On the other hand, reduced coverage of the obese population (adults and young people) has been largely ignored.
“I’m not sure why the effectiveness of vaccines in this population has not been better reported,” said Catherine Andersen, assistant professor of biology at Fairfield University, who studies obesity and metabolic diseases. “This is a missed opportunity for further public fitness intervention.”
In 2017, UNC-Chapel Hill scientists provided a key clue to the limitations of the flu vaccine. In a paper published in the International Journal of Obesity, they showed for the first time that vaccinated obese adults were twice as likely as healthy-weight adults to expand influenza or a flu-like disease.
Surprisingly, they found that obese adults produced a point of antibodies opposed to the flu vaccine, but that they continued to respond poorly.
“It’s the mystery,” said Chad Petit, a flu virologist at the University of Alabama.
One hypothesis, Petit said, is that obesity can cause metabolic deregulation of T cells, the white blood cells of the immune response. “It’s not second to none,” said Petit, who investigates COVID-19 in obese patients. “We can design better vaccines that can succeed over this gap.”
Historically, other people with a higher BMI have occasionally been excluded from drug trials because they suffer from chronic diseases that can mask the results. Ongoing clinical trials to verify the protection and efficacy of a coronavirus vaccine do not come to the exclusion of BMI and will come with obese individuals, said Dr. Larry Corey of the Fred Hutchinson Cancer Research Center, which oversees Phase 3 trials sponsored by the National Institutes of Health.
Although trial coordinators do not do so in particular about obesity as a prospective complication, Corey said, the participants’ BMI will be documented and the effects assessed.
Dr. Timothy Garvey, endocrinologist and director of diabetes studies at the University of Alabama, was one of those who noted that, despite persistent questions, it is safer for obese people to get lost.
“The flu vaccine still works in obese patients, but not so well,” Garvey said. “We need them to be drained.”
More than 107 million American adults are obese and their ability to safely repaint, care for their families and return to life may be reduced if the coronavirus vaccine provides them with low immunity.
In March, even at the beginning of the global pandemic, an unnoticed examination of China found that Chinese patients heavier with COVID-19 were more likely to die than the thintest, suggesting a long-term expected dangerous term in the United States, whose population is among the heaviest. around the world.
And then came that long term.
While extensive care centers in New York, New Jersey and patient-filled, the Federal Centers for Disease Control and Prevention warned that obese Americans with a frame mass index of 40 or more, known as morbid obesity or approximately one hundred pounds of obesity, were among the teams at risk of seriously falling ill with COVID-19. Approximately 9% of U.S. adults fall into this category.
As the weeks passed and a clearer picture of hospitalized patients emerged, federal fitness officials expanded their warnings to include others with a body mass index of 30 or more. This has particularly expanded the ranks of those vulnerable to the most severe cases of infection, to 42.4% of American adults.
Obesity has long been known to be a major threat to death from cardiovascular disease and cancer. But scientists in the emerging immunometabolism chart find that obesity also interferes with the body’s immune response, exposing other obese people to a greater threat of infection with pathogens such as influenza and the new coronavirus. In the case of influenza, obesity has become something that makes it harder for adults to breasts rather than infection. This is whether this will be true for COVID-19.
A healthy immune formula activates and disables inflammation as needed, white blood cells and the delivery of proteins to fight infections. Vaccines exploit this inflammatory response. But blood tests show that other obese people and others with metabolic threat points, such as high blood pressure and higher blood sugar level, delight in a state of mild chronic inflammation; inflammation turns on and stays on.
Fatty tissue in the stomach, liver and other organs is not inert; specialized cells that send molecules, such as the hormone leptin, that scientists suspect induce this state of chronic inflammation. While precise biological mechanisms are still being studied, chronic inflammation appears to interfere with the immune reaction to vaccines, which in all likelihood subjects other obese people to preventable diseases even after vaccination.
An effective vaccine feeds a controlled burning inside the body, burning in cellular reminiscences a simulated invasion that never occurred.
Evidence that obese Americans have a strong reaction to non-unusual vaccines was first observed in 1985 when obese hospital workers who won the hepatitis B vaccine showed a significant minimum in coverage 11 months later that it was not observed in non-obese workers. This discovery was replicated in a follow-up study that used longer needles to ensure that the vaccine was injected into the muscle and not fat.
Researchers have discovered similar disorders with the hepatitis A vaccine, and other studies have shown a significant decrease in antibody coverage induced by tetanus and rabies vaccines in obese people.
“Obesity is a serious global problem, and the suboptimal immune responses induced by the vaccine seen in the obese population should be ignored,” researchers from the Mayo Clinic Vaccine Research Group argued in a 2015 study published in the journal Vaccine.
Vaccines are also known to be less effective in the elderly, which is why other people age 65 and older get a supercharged flu vaccine each year that contains many more influenza virus antigens to help their immune response.
On the other hand, reduced coverage of the obese population (adults and young people) has been largely ignored.
“I’m not sure why the effectiveness of vaccines in this population has not been better reported,” said Catherine Andersen, assistant professor of biology at Fairfield University, who studies obesity and metabolic diseases. “This is a missed opportunity for greater public physical fitness intervention.”
In 2017, UNC-Chapel Hill scientists provided a key clue to the limitations of the flu vaccine. In a paper published in the International Journal of Obesity, they showed for the first time that vaccinated obese adults were twice as likely as healthy-weight adults to expand influenza or a flu-like disease.
Surprisingly, they found that obese adults produced a point of antibodies opposed to the flu vaccine, but that they continued to respond poorly.
“It’s the mystery,” said Chad Petit, a flu virologist at the University of Alabama.
One hypothesis, Petit said, is that obesity can cause metabolic deregulation of T cells, the white blood cells of the immune response. “It’s not second to none,” said Petit, who researches COVID-19 in obese patients. “We can design better vaccines that can succeed over this gap.”
Historically, other people with a higher BMI have occasionally been excluded from drug trials because they suffer from chronic diseases that can mask the results. Ongoing clinical trials to verify the protection and efficacy of a coronavirus vaccine do not come to the exclusion of BMI and will come with obese individuals, said Dr. Larry Corey of the Fred Hutchinson Cancer Research Center, which oversees phase 3 trials sponsored through the National Institutes of Health.
Although trial coordinators do not do so in particular about obesity as a prospective complication, Corey said, the participants’ BMI will be documented and the effects assessed.
Dr. Timothy Garvey, endocrinologist and director of diabetes studies at the University of Alabama, was one of those who noted that, despite persistent questions, it is safer for obese people to get lost.
“The flu vaccine still works in obese patients, but not so well,” Garvey said. “We need them to be drained.”
We inspire organizations to republish our content, for free. Here’s what we’re asking:
You must credit us as an original publisher, with a link to our site khn.org. If possible, come with the original authors and “Kaiser Health News” at the signature. Please keep the links in the story.
It is vital to note that you should not take everything in khn.org for republication. If a story is classified as “All Rights Reserved”, we cannot grant permission to republish that article.
Do you have any questions? Let us know [email protected]
Thank you for your interest in supporting Kaiser Health News (KHN), the country’s leading nonprofit and fitness policy writing room. We distribute our journalism without fees and advertising through media partners of all sizes and in small, giant communities. We appreciate all the commitment bureaucracy of our readers and listeners, and we appreciate your support.
KHN is an editorially independent program of KFF (Kaiser Family Foundation). You can KHN by making a contribution to KFF, a nonprofit charity that is not related to Kaiser Permanente.
Click the button below the KFF donation page that will provide more information and FAQs. Thank you!